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In this issue of Blood, Kung Sutherland et al report on the preclinical activity of SGN-CD33A, a humanized anti-CD33 antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker, against acute myeloid leukemia (AML) cells in vitro and in vivo. Even though CD33 is an antigen that is both considered to be expressed in more committed myeloid precursors 2, 3 and is not present in AML stem cells, the clinical relevance of CD33 as a target is validated by survival benefit with GO in subgroups of patients with AML in randomized clinical trials. [4] [5] [6] There is a distinct need in the field for CD33-based ADCs to quickly fill the void left by the withdrawal of GO from the market, and the rapid preclinical and clinical development of agents such as SGN-CD33A is needed.
Conflict-of-interest disclosure:The author declares no competing financial interests. n A mouse model of hemolytic disease of the newborn In this issue of Blood, Stowell et al describe a novel mouse model of hemolytic disease of the fetus and newborn (HDFN) that recapitulates many of the key features of human disease. 1 Recently, this same group of researchers described a transgenic mouse that expresses the human KEL2 (Chellano) red cell surface protein from the Kell system on red cells, 2 and subsequently demonstrated that Kell differences on transfused blood induce antibody responses and hemolytic transfusion reactions similar to those seen in patients. 3 In this latest report,
Stowell et al 1 demonstrate that similar to some patients, Kell differences between mother and father can lead to maternal antibody generation and hemolytic disease in utero. In so doing, they provide experimental confirmation of a long sought after animal model of HDFN.
H DFN can be thought of as a clinically relevant natural experiment in human immunology, whereby allogenic paternal proteins expressed on red blood cells in the fetus are capable of elucidating a class switched, IgG alloantibody response in the mother. 4 Exposure to red cell antigens typically occurs at the time of delivery, sparing the initial pregnancy. However, with subsequent pregnancies, transfer of maternal IgG to the developing fetus leads to antibody binding and destruction of developing fetal red blood cells. Alternatively, exposure of women of child-bearing age to paternal red cell antigens via transfusion can lead to antibody production capable of impacting even the first pregnancy. Classically, antibody titers and disease severity both increase with subsequent pregnancies; with lower titers associated with neonatal anemia and hyperbilirubinemia and higher titers associated with erhythroblastosis fetalis and interuterine death. figure) . By using mothers that are genetically incapable of antibody production, they definitively demonstrate that these antibodies drive the observed pathology (see figure) .
Despite the initial description of HDFN in 1609 by a French midwife and the discovery of the antibody-mediated disease mechanism underlying it in the 1940s, 4 our understanding of the basic immune mechanisms that govern induction of antibody responses in the relatively immunosuppressive environment of pregnancy remains unclear.
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